IN BRIEF: PureTech Health's Akili secures USD160 million in financing

Wed, 26th May 2021 18:03

PureTech Health PLC - clinical-stage biotherapeutics company - Notes investee Akili Interactive has secured USD160 million of combined equity and debt financing. Says funding will accelerate commercialization of Akili's flagship treatment EndeavorRx, enable expansion of Akili's core technology to treat acute and chronic cognitive disorders, and drive further research and development of new technologies to treat broader range of conditions.

Current stock price: 378.50p

Year-to-date change: down 5.4%

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Related Shares

More News

29 May 2024 21:30

IN BRIEF: PureTech's Ankili to be acquired by Virtual Therapeutics

PureTech Health PLC - London-listed Biotech company headquartered in Boston - Says Tuesday that founded entity, Ankili Inc, a game developer focusing ...

21 May 2024 14:07

PureTech-founded Vedanta begins trials for VE303 colonic bacteria drug

(Alliance News) - PureTech Health PLC on Tuesday said that a company it founded and in which it maintains a stake had begun trials of a new treatment ...

20 May 2024 10:13

PureTech Health launches $100m tender offer

(Sharecast News) - Clinical-stage biotherapeutics company PureTech Health launched a proposed $100m tender offer on Monday, aiming to repurchase share...

20 May 2024 09:03

IN BRIEF: PureTech Health launches USD100 million buyback programme

PureTech Health PLC - London-based biotherapeutics company - Launches tender offer to repurchase shares for a maximum consideration of USD100 million....

10 May 2024 16:39

EARNINGS AND TRADING: Asiamet Resources declares special dividend

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately report...